Kestra Medical Q4 2026 Results Overview
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reported fourth‑quarter revenue of $28.6 million, surpassing the analyst consensus estimate of $26.5 million and representing a 66 % increase from $17.2 million in the comparable prior‑year quarter. The company posted a loss of $0.67 per share, wider than the $0.58 per‑share loss forecast by analysts.
For the full fiscal year 2026, revenue totaled $95.1 million, up 59 % from $59.8 million in fiscal 2025. Gross margin expanded to 54.8 % in the quarter, compared with 44.3 % in the prior year period, reflecting volume leverage, a higher mix of in‑network patients, and cost‑improvement initiatives. The ASSURE wearable cardioverter‑defibrillator system protected 18,000 patients during fiscal 2026, and the company wrote 6,357 prescriptions for the system in the quarter, a 63 % year‑over‑year increase.
President and CEO Brian Webster said the quarter demonstrated “strong financial performance, generating revenue growth of 66 % while expanding gross margin to 55 %.”
Looking ahead, Kestra provided fiscal 2027 revenue guidance of $137 million, indicating an expected 44 % growth versus fiscal 2026. At quarter‑end, cash, cash equivalents and investments amounted to $262.2 million.
Shares were largely unchanged after the announcement, with after‑hours trading showing a 2.34 % decline.